ArticleAsian Pacific journal of cancer prevention : APJCP2026
The Non-Coding Code: Silent Regulators of MEG3 and Let-7i-3p/5p in the Progression of Acute Lymphoblastic Leukemia.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAcute lymphoblastic leukemia (ALL) is one of the most common malignancies worldwide. The long non-coding RNA MEG3 functions as a tumor suppressor in several cancers, potentially influencing gene expression through transcriptional, translational, and epigenetic mechanisms. let-7i plays a role in leukemia progression. This study aimed to evaluate MEG3 gene expression in adult ALL patients and investigate its possible regulatory interaction with let-7i-3p and let-7i-5p.
methodsA total of 83 blood samples, classified in a case-control study design, were collected from newly diagnosed ALL patients (n=53) and healthy controls (n=30). Hematological parameters were estimated using a CBC analyzer. RNA was extracted and reverse-transcribed into cDNA. Quantitative real-time PCR with gene-specific primers was employed to assess MEG3 and let-7i-3p/5p expression levels.
resultsALL patients and healthy controls were matched for age (29.0±9.9 vs. 28.6±7.7 years, p=0.862) and sex (p=0.299). Hematological analysis revealed significant cytopenias in patients, including reduced Hemoglobin (Hb) (8.60±1.75 vs. 14.72±2.51 g/dL; p<0.001), white blood cells (WBCs) (4.91±2.84 vs. 7.96±1.57×109/L; p<0.001), and platelets (PLT) (156.96 ± 35.64 vs. 269.93±55.35×109/L; p<0.001). Gene expression analysis revealed that MEG3 was significantly downregulated in ALL patients (fold change 0.535±0.273; p=0.001), whereas Let-7i-3p/5p were upregulated (fold changes 1.875 ± 0.732 and 1.857 ± 0.891: p=0.003 and 0.004, respectively), indicating a different dysregulation pattern associated with adult ALL.
conclusionThis study demonstrates that adult ALL patients exhibit hematological abnormalities including anemia, leukopenia, and thrombocytopenia. Molecular analysis revealed a significant downregulation of lncRNA MEG3, alongside upregulation of let-7i-3p/5p, suggesting their potential involvement in leukemogenesis. These findings highlight the diagnostic and possibly prognostic relevance of MEG3 and let-7i in adult ALL and provide a basis for further investigation into their mechanistic roles and therapeutic targeting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.